KALA BIO, Inc. 8-K

What Happened
KALA BIO, Inc. announced it received a letter from Nasdaq on January 20, 2026, notifying the company that its common stock failed to meet the $1.00 minimum closing bid requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq reviewed the closing bid for 30 consecutive business days from December 3, 2025, through January 16, 2026. The company has a 180-calendar-day compliance period, until July 20, 2026, to regain compliance.

Key Details

• Nasdaq found the deficiency based on the 30-business-day period ending January 16, 2026.
• To regain compliance, KALA must have a minimum closing bid of $1.00 for at least 10 consecutive business days during the compliance period.
• If eligible, the company may request a second 180-day cure period by meeting market value and other initial listing standards (except the bid-price rule) and providing notice—this could include effecting a reverse stock split.
• The notice does not immediately affect trading; the stock remains listed while the company works to cure the deficiency, though Nasdaq could later issue a delisting notice if noncompliance continues.

Why It Matters
A continued failure to meet Nasdaq's $1.00 bid-price rule could lead to delisting, which often reduces liquidity and can limit investor access to the stock. Retail investors should be aware of the July 20, 2026 deadline and monitor company announcements for any actions (such as a reverse stock split or other measures) that KALA may take to regain compliance or any Nasdaq updates about listing status.